$MDLN News

BTIG Reiterates Buy on Medline, Maintains $55 Price Target

Reported Earlier, FDA Says Medline Issued Correction For Convenience Kits Containing B. Braun Bupivacaine Hydrochloride Components, Identified As Most Serious Recall Type; B. Braun Reported 35 Serious Injuries, No Deaths

JP Morgan Maintains Overweight on Medline, Lowers Price Target to $46

Wells Fargo Maintains Equal-Weight on Medline, Lowers Price Target to $34

TD Cowen Maintains Buy on Medline, Lowers Price Target to $45

RBC Capital Maintains Outperform on Medline, Lowers Price Target to $46

Truist Securities Maintains Buy on Medline, Lowers Price Target to $47

Evercore ISI Group Maintains Outperform on Medline, Lowers Price Target to $39

Stifel Maintains Buy on Medline, Lowers Price Target to $45

Medline Inc. (MDLN) Q2 2026 Earnings Call Transcript

Medline (NASDAQ:MDLN) Tumbles as Q2 Earnings Beat Offset by Lowered Full-Year EBITDA Guidance

Medline Inc. 2026 Q2 - Results - Earnings Call Presentation

Medline Q2 Adj. EPS $0.50 Beats $0.32 Estimate, Sales $7.685B Beat $7.512B Estimate

BTIG Reiterates Buy on Medline, Maintains $55 Price Target

Reported July 22: Medline Recalls Specific Medline Kits Having B. Braun Convenience Kits That Include Bupivacaine Hydrochloride In Dextrose Injection

Medline Strikes New Prime Vendor Agreement To Offer Access To Its Portfolio Of Medical-Surgical Products For Its Hospital, Physician Office Sites To Allina Health

Medline: After IPO In 2025, This Year Is A Bet On Continued Growth

ICUI or MDLN: Which Is the Better Value Stock Right Now?

Here is Why Medline (MDLN) is One of the Best Young Stocks with the Highest Upside Potential

Is Medline (MDLN) One of the Best Healthcare Stocks to Buy With the Highest Upside Potential?